Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084)

Trial Profile

Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084)

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Hepatitis A-hepatitis B vaccine (Primary)
  • Indications Hepatitis A; Hepatitis B
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 17 Nov 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 16 Sep 2014 Planned initiation date changed from 1 Jul 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
    • 30 May 2014 Planned initiation date changed from 1 May 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top